Why to invest in SCHOTT Pharma

Global market leader in a highly attractive and protected industry

Global market leader in a highly attractive and protected industry

Pure player in injectables benefiting from healthcare megatrends

Pure player in injectables benefiting from healthcare megatrends

Strong shareholder value – high profitability and strong financials

Strong shareholder value – high profitability and strong financials

Pioneers and innovators shaping the industry since 1923

Pioneers and innovators shaping the industry since 1923

A long-term strategy with the right backing

A long-term strategy with the right backing

OUR EQUITY STORY

"

Leveraging our global position and trusted partnerships, SCHOTT Pharma is well-positioned to pursue exciting opportunities in the growing market for injectables and biologics. Our strong-margin, high-value solutions, such as prefillable syringes and ready-to-use solutions, enable us to meet the increasing demand to safely store and deliver the next generation of drugs.

 

Andreas Reisse, CEO SCHOTT Pharma

Andreas Reisse

SCHOTT Pharma in numbers (FY 2023)

m €
Revenues
m €
EBITDA
m €
CapEx
bn
Units produced p.a.
Patents

Annual Report 2022/2023 (Online)


Annual Report

Latest publications

Q3 statement / Q3 financial report 2023/2024
Thursday, August 29, 2024 | Quarterly reports
Quarterly statement 9M 2023/20...
Presentation 9M 2023/2024
Thursday, August 29, 2024 | Presentations
Presentation 9M 2023/2024
Half-yearly financial report 2023/2024
Thursday, June 27, 2024 | Quarterly reports
Half-year report H1 2023/2024
ALL PUBLICATIONS

Financial events

December 12, 2024
Publication Annual Financial R...
February 04, 2025
Annual General Meeting
February 13, 2025
Quarterly statement (Q1 2024/2...
ALL EVENTS

Get in touch

Tobias Erfurth

Head of Investor Relations

If you are a journalist, please contact our Corporate Communications team.